Showing 30 of 4110 posts
RWS completed its Obviously Group acquisition on 5 May 2026, paying £16.5m upfront with up to £23.5m contingent on future performance.
JoshuaMay 6, 2026
B90 Holdings more than doubles revenue and returns to profit, but auditor flags material uncertainty over a €0.6m legacy liability.
JoshuaMay 6, 2026
Ramsdens upgrades FY26 profit guidance again to at least £28.5m, driven by soaring gold prices and strong performance across pawnbroking, jewellery, and foreign currency.
JoshuaMay 6, 2026
Next PLC Q1 sales beat forecasts, profit guidance raised despite Middle East disruption. Online strength offsets retail weakness.
JoshuaMay 6, 2026
Wetherspoon sales rise 3.4% but cost pressures may push profits below expectations. A mixed Q3 update for investors.
JoshuaMay 6, 2026
Renishaw reports record Q3 revenue, accelerating growth and a rising order book, with FY2026 guidance maintained. Strong semiconductor demand drives momentum.
JoshuaMay 6, 2026
Reach PLC Q1: Digital revenue down 8.1% on search disruption, but full-year guidance held steady.
JoshuaMay 6, 2026
Trainline FY2026: profit growth beats revenue as EBITDA rises 11%, net ticket sales up 7%, despite UK commission headwinds.
JoshuaMay 6, 2026
Smith+Nephew Q1 2026: 3.1% underlying growth, $500M buyback, guidance unchanged. Sports medicine strong, US knees weak but no nasty surprises.
JoshuaMay 6, 2026
Coiled Therapeutics' annual report reveals a strategic reset around AO-252 with 80% clinical benefit rate, but heavy dilution and pre-revenue status remain high-risk.
JoshuaMay 6, 2026
Animalcare delivers strong FY25 results with 52.6% EBITDA growth, boosted by Randlab, as the recommended Charterhouse takeover at 336p takes centre stage.
JoshuaMay 6, 2026
Portmeirion Group's 2025 results: loss from US tariffs, but strategic transformation and stronger Q1 2026 trading offer cautious optimism.
JoshuaMay 6, 2026
RWS's initial agreement in principle to buy Obviously for up to £40m, including the target's financials and risks. The deal completed later on 5 May 2026.
JoshuaMay 5, 2026
Fusion Antibodies reports 9% revenue growth, margins up to 50%, cash doubles to £1m+, and strategic wins with larger pharma clients. Cautiously optimistic FY2027 outlook.
JoshuaMay 5, 2026
Autins Group returns to net profit with major contract wins and margin expansion, despite lower revenue. Encouraging FY27-28 outlook.
JoshuaMay 5, 2026
Kosmos Energy's record Q1 production drives positive free cash flow and a 20% debt reduction target after bond deal, equity raise, and asset sale.
JoshuaMay 5, 2026
AEP Plantations buys PT Pinago Utama Tbk for $162M in cash, boosting CPO output by 25% with immediate earnings accretion.
JoshuaMay 5, 2026
Camellia swings to £1.0m trading profit in FY25, with VEP progress and balance sheet strength, but statutory losses remain.
JoshuaMay 5, 2026
Vodafone buys full control of VodafoneThree for £4.3bn, gaining 100% of UK’s largest mobile network with £700m synergy target.
JoshuaMay 5, 2026
Invinity accelerates cost reduction (66% target) and unveils £14m-£234m revenue outlook for 2026-2028, but Hungary delays temper short-term optimism.
JoshuaMay 5, 2026
Crimson Tide returns to profitability in FY26 with improved cash generation, but high churn remains a key risk for future growth. Read the full analysis.
JoshuaMay 5, 2026
Air Astana Q1 2026: revenue up 13% but profits plunged as costs surged. Engine problems and Gulf conflict hurt margins. March recovery gives hope.
JoshuaMay 5, 2026
MHP SE 2025 results: revenue up 24%, net profit rises to $187m, UVESA acquisition boosts European presence. But margins slip to 10%, debt higher. Full analysis.
JoshuaMay 5, 2026
Hemogenyx Pharmaceuticals 2025 final results: Phase 1 HG-CT-1 trial progresses with DSMB clearance, but losses and dilution continue. Full analysis.
JoshuaMay 1, 2026
First Class Metals annual results: Sunbeam promising, but cash just £77k highlights funding risk. Asset monetisation key. Better rocks, tight balance sheet.
JoshuaMay 1, 2026
Africa Opportunity Fund's 2025 NAV jumps 26% to $1.51/share, but market cap stagnates-a deep discount persists as the fund pivots from liquidation to growth.
JoshuaMay 1, 2026
Santander UK completes £2.65bn TSB acquisition, boosting market position with £400m cost synergy target and 16% RoTE goal by 2028.
JoshuaMay 1, 2026
Pearson Q1 2026: 4% underlying sales growth with Virtual Learning surging 21%. Full-year guidance unchanged after a solid start.
JoshuaMay 1, 2026
NewRiver REIT delivers strong FY results with Capital & Regional integration complete, £6.2m synergies, resilient leasing and a strengthened balance sheet.
JoshuaMay 1, 2026
ProService: FY26 revenue miss, EBITDA breakeven. Refinancing overhang & FY27 guidance slashed. Speedy Hire deal shows promise but slow ramp-up. Full insight.
JoshuaMay 1, 2026